Loading...
The application of nucleoside analogue–based chemotherapy and immunotherapy with rituximab or alemtuzumab has increased both response rates and duration in patients with chronic lymphocytic leukemia (CLL). However, because none of these therapies is curative, sequential therapeutic regimens are required.
In an industry-supported study of a potentially therapeutic agent, investigators tested the immunomodulatory drug lenalidomide (Revlimid) in relapsed CLL patients and correlated response with prognostic markers and plasma cytokine levels. The researchers evaluated 44 heavily pretreated patients (median number of prior therapies, 4; range, 1–5). Patients received lenalidomide on a continuous daily oral dosing schedule: A starting dose of 10 m…